Dr. Frigault is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Zero Emerson Place, Suite 118
c/o Kerri Tortora
Boston, MA 02114Phone+1 617-726-5765
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2015 - 2017
Johns Hopkins UniversityResidency, Internal Medicine, 2012 - 2015
Perelman School of Medicine at the University of PennsylvaniaClass of 2012
Certifications & Licensure
MA State Medical License 2015 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- TriPRIL CAR T Cells in Multiple Myeloma Start of enrollment: 2021 Oct 05
Roles: Principal Investigator, Contact
- CAR-37 T Cells In Hematologic Malignancies Start of enrollment: 2020 Jun 19
Roles: Contact, Principal Investigator
- Tisagenlecleucel In Primary CNS Lymphoma Start of enrollment: 2019 Dec 11
Roles: Contact, Sponsor-Investigator, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 69 citationsImmune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.Melissa R Hines, Tristan E Knight, Kevin O McNerney, Mark B Leick, Tania Jain
Transplantation and Cellular Therapy. 2023-07-01 - 225 citationsCardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)Raza M. Alvi, Matthew J. Frigault, Michael G. Fradley, Michael D. Jain, Syed S. Mahmood
Journal of the American College of Cardiology. 2019-12-24 - 292 citationsNCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand
Journal of the National Comprehensive Cancer Network. 2020-03-01
Abstracts/Posters
- Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic DiseasesMatthew J. Frigault, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML)Matthew J. Frigault, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...Matthew J. Frigault, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Engineering an Optimized Trimeric APRIL-Based CAR to Broaden Targetability of Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
$1 Million Gift to Mass General Cancer Center Will Support Promising Research Conducted by Pioneering Physician-ScientistsOctober 21st, 2024- Investigational CAR-T Shows Promise for Advanced Multiple MyelomaJune 5th, 2022
- Arcellx Provides Business Updates and Reports First Quarter 2022 Financial ResultsMay 12th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
